Bio-Rad Laboratories, Inc.
BIO
$279.03
-$5.65-1.99%
NYSE
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 6.16% | 0.21% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 6.16% | 0.21% | |||
| Cost of Revenue | 12.31% | 1.31% | |||
| Gross Profit | 0.58% | -0.75% | |||
| SG&A Expenses | 6.46% | -0.39% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.00% | 2.27% | |||
| Operating Income | -9.71% | -14.57% | |||
| Income Before Tax | 315.54% | -204.13% | |||
| Income Tax Expenses | 334.53% | -192.72% | |||
| Earnings from Continuing Operations | 310.59% | -207.58% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 310.59% | -207.58% | |||
| EBIT | -9.71% | -14.57% | |||
| EBITDA | -7.40% | -6.66% | |||
| EPS Basic | 310.17% | -208.79% | |||
| Normalized Basic EPS | 14.00% | -10.59% | |||
| EPS Diluted | 309.83% | -208.83% | |||
| Normalized Diluted EPS | 13.85% | -10.59% | |||
| Average Basic Shares Outstanding | 0.20% | -1.11% | |||
| Average Diluted Shares Outstanding | 0.33% | -1.12% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||